Introduction
Non-Hodgkin's lymphoma (NHL) represents a heterogeneous group of lymphocyte malignancies. In general, despite being sensitive to radiation therapy and chemotherapy, low grade NHL remains an incurable disease. In most cases, patients respond to the initial treatment, but half of those relapse within 10 years. Relapsed patients are retreated but there is often a shorter duration of each remission. In addition, some patients become refractory to the treatment regimen [1] [2] [3] . A great deal of effort has been made to improve the treatment of NHL to achieve a longer duration of response.
However, despite new chemotherapeutic agents that have been introduced and established into the clinical treatment during the last several decades, overall survival for NHL patients has not essentially changed over the past 40 years 4 . In the 1970's, Köhler and Milstein 5 developed the technique for large-scale production of monoclonal antibodies making possible the anti-tumor therapy using monoclonal antibodies. The first B-cell specific antibody B1 was identified in 1981 by Nadler et al. 6 . Subsequent investigations demonstrated the therapeutic potential of anti-CD 20 immunoglobulins 7, 8 . In the late 1990's, another anti-CD 20 monoclonal antibody, rituximab, was developed and subsequently approved by the United States Food and Drug Administration (FDA) for treatment of patients with low grade B-cell lymphoma who have relapsed. Rituximab is a chimeric monoclonal antibody which is derived from the murine antibody, ibritumomab, and is marketed as Rituxan ® /Mab Thera ® . Initially, rituximab was used in combination with standard chemotherapeutic options and as a single agent for treatment of elderly NHL patients. The results showed improvement in outcome, overall response rate and duration of remissions [9] [10] [11] [12] . Recent advances in molecular medicine have provided a novel approach to the treatment of NHL. During the early decades of the 21 st century, therapy with radiolabeled monoclonal antibodies became a treatment option. Radioimmunotherapy (RIT) is based on the concept of conjugation of a radionuclide to a monoclonal antibody that would deliver localized radiation to an antigen that is expressed on tumor cells. RIT targets the cytotoxic radiation to the tumor cells with minimal irradiation of normal cells. RIT the most appropriate for treatment of multiple tumor sites that cannot be readily excised surgically or irradiated using external beam radiation or brachytherapy.
The US FDA has approved 2 RIT protocols: the first in 2002, Zevalin ® -rituximab and 90 Y-ibritumomab, and the second in 2003, or Bexxar ® -tositumomab and 131 Itositumomab. The primary indication for these agents was treatment of relapsed, refractory, or transformed CD20+B-cell NHL. Treatment with either agent is based on monoclonal antibodies specific for the CD20 surface antigen found on normal B-cells and more than 90% of B-cell NHL. In fact, CD20 is an epitope (antigen) expressed on pre-B and mature B-cells, but not on early precursors, stem cells or plasma cells [13] [14] [15] [16] [17] . This represents an excellent target as Bcell precursors and plasma cells are not targeted by anti-CD20 antibodies 18 . Moreover, the bound antibody is not shed and is minimally internalized resulting in antibodydependent and complement-mediated cytotoxicity as well as apoptosis [19] [20] [21] . Both RIT agents target the CD surface antigen. Zevalin ® utilizes 90 Y, and is a pure β emitter with a 2.7 days of half-life, energy of 2.3 MeV, and maximal tissue penetration of 5 mm. Since there are no gamma emissions in the decay spectrum of this isotope, it is poorly visualized on gamma cameras. Therefore, 111 In was used until recently in the US for pretreatment imaging and evaluation of biodistribution. In contrast, Bexxar ® , is a directly radiohalogenated β and γ emitter; with a γ emission spike of 0.36 MeV, β energy emission of 0.6 MeV. Thus, it can be readily visualized on a gamma camera. Furthermore, Bexxar ® involves a covalent bond between I-131 and monoclonal antibody, while Zevalin ® uses chelation complex thus providing noncovalent linkage for the radiometal (Table 1) 22 .
Zevalin
® increases the efficacy of anti-CD20 antibody therapy due to the conjugation of monoclonal antibody with a beta-emitting radionuclide ( 90 Y) 15, 23, 24 . This specific treatment is based on direct toxicity delivered to the cell bound by the antibody and to the neighboring tumor cells via cross-fire effect. Beta particles thus kill cells in the nearby environment which are either not accessible to the monoclonal antibody, or may not express CD20, and/or that may be resistant to the immune-mediated or direct apoptotic effects of the unlabeled antibody 25 18 . Nevertheless, despite the excellent clinical responses, the utilization of these products has been disappointing. Consequently in early 2014, Bexxar ® was withdrawn from the market by the manufacturer and is no longer available.
Eligibility criteria
RIT is approved for patients with low-grade follicular lymphoma that relapsed after the treatment with rituximab or are refractory or failed to respond to rituximab. As stated, recently the indications for use have been extended to include consolidation therapy in patients with a complete response or at least partial response. This treatment is also used in patients with large B-cell lymphoma that express the CD-20 epitope. Before administration of RIT, patients have to meet the following criteria: initial biopsy confirmation of NHL with the expression of CD20 epitope; recent (within 4-6 weeks) bone marrow biopsy to confirm less than 25% involvement, because treatment of patients with 25% or more bone marrow involvement is associated with severe bone marrow toxicity; history of allergies or medications; and recent (within 1-2 weeks) complete blood count (a platelet count greater than 150,000 justifies full dose, while platelet counts between 100,000 and 150,000 require a modified amount of radiolabeled antibody). This treatment should not be performed in patients younger than 18 years or pregnant and lactating women 18 . 22 . Without prior infusion of cold antibody, administration of radiolabeled antibody would result in rapid binding of activity by circulating lymphocytes and clearance by those stored in the spleen. When the radiolabeled antibody is injected after the cold antibody, the sites in the spleen have been already saturated and a greater portion of injected labeled antibody remains in the circulation and increases the percentage of the administered dose in tumor 18 .
Treatment regimens
The protocol of the Zevalin ® regimen is described in detail in our previous reviews 26, 27 . The dosing regimen for treatment with Zevalin ® starts with a pre-dose of rituximab 250 mg/m 2 on the first day. The same dose of rituximab (250 mg/m 2 ) is repeated one week later, followed by the 90 Yibritumomab tiuxetan infusion in a dose dependent on the platelet counts (30 MBq/kg if platelets exceed 150,000/mL; 22.5 MBq/kg if platelets are > 100,000/mL, < 150,000/mL). The maximum dose should not exceed 1.18 GBq (Figure 1 ).
Fig. 1 -The Zevalin
® treatment regimen for non-Hodgkin lymphoma.
Patients receiving Bexxar ® should be premedicated with a saturated solution of potassium iodide, to block or to reduce thyroidal iodine uptake (3 drops saturated solution of potassium iodide diluted in water 2 times per day, beginning the day before the protocol initiation and continuing for 3 weeks). The Bexxar ® regimen consists of 2 steps, the first being, dosimetric and the second, therapeutic 27 . The dosimetric phase involves 3 whole body scans (24-48 h apart) during the week after a dosimetric dose of 185 MBq of 131 Itositumomab preceded by an infusion of 450 mg of unlabeled tositumomab. The Bexxar ® regimen is completed seven to nine days after the initial infusion, with the infusion of 450 mg of unlabeled tositumomab followed by the 131 Itositumomab therapeutic dose ( Figure 2 ). For dosimetry, whole body counts are calculated from the total counts on the anterior and posterior whole body scans performed one h after the infusion, 2 and 4-5 days after the initial infusion. The residency time is determined by setting the initial whole body counts as 100% and plotting the other data on a semilog plot. Residence time is at the 37% intercept. This value is used in the calculation of the dose of radioactivity to be administered. Patients with a platelet count exceeding 150,000/mL would receive the maximum tolerated dose of 75 cGy whole-body radiation absorbed dose, while 65 cGy whole-body radiation absorbed dose is optimal for patients with platelet counts between 100,000/mL and 150,000/mL 18 . Fig. 2 Table 2 . A single-arm phase II clinical trial was performed on 57 follicular B-cell NHL patients who relapsed or were refractory to the prior rituximab treatment. Patients achieved 74% overall response rate (ORR) and 15% CR. Estimated median duration of response (MDR) was 6.4 months and time to progression (TTP) was 6.8 months for all patients and 8.7 months for responders 24 . A randomized, phase III multicenter study involving 27 institutions and 143 patients with relapsed or refractory low-grade, follicular, or transformed NHL was performed. All patients had advanced disease with a median of two prior chemotherapy regimens. Seventy three patients received Zevalin ® , and 70 patients received 4 doses of rituximab. RIT group was pretreated with two rituximab doses to improve biodistribution. 34 studied 414 patients with advanced stage follicular lymphoma who had been enrolled in 77 centers. A large group of 208 patients who received consolidation therapy [chemotherapeutic induction of CR and partial response (PR)] in contrast to a similar group of patents after first line induction treatment without additional treatment were compared. They detected that consolidation induced significantly longer median PFS in the control group (36.5 vs 13.3 months). Moreover, 77% of patients with PR after induction treatment converted to CR after consolidation treatment. The final CR rate was 87.4% after consolidation with Zevalin ® compared to 53.3% to the control group. Table 3 shows the clinical efficacy in several single arm trials on the Bexxar ® regimen in previously treated NHL patients. Kaminski et al. 35 performed a pivotal study on 60 patients with chemotherapy-refractory low-grade or transformed low grade B-cell NHL. They compared the efficacy of Bexxar ® regimen to the last qualifying chemotherapy obtaining ORR of 65% vs 28%, respectively. Twenty percentage of patients achieved CR on 131 I tositumomab with MDR of 6.5 months and TTP of 8.4 months. Fisher et al. 36 enrolled 250 previously treated relapsed or refractory lowgrade, follicular, or transformed low-grade NHL patients in five clinical trials. Bexxar ® regimen was administered in NHL patients who were previously treated with chemother-apy or rituximab (50% of them did not respond to the last treatment). Data of the integrated patient population indicated ORR and CR rates of 56% and 30%, respectively, with MDR of 12.9 months and median TTP of 15 months (in patients with a complete response, MDR was 58.4 months and TTP 48.5 months). ORRs and CR differ among each of five clinical trials, ranging from 47-68% and 20-38%, respectively; with the median follow-up of 41.5 months. For the durable response population (32% of the entire patient population), CR was 77%; MDR 45.8 months with a median follow-up of 61.2 months 36 . Updating the long-term data on chemotherapy-relapsed/refractory patients treated with Bexxar ® in the phase 1-2 single-center study, Kaminski et al. 37 detected 71% ORR and 34% CR with TTP of 12 months during the follow-up of 37.2 months. They showed better ORR in transformed low-grade lymphoma compared to newly diagnosed intermediate-grade tumors (79% vs 41%), with 50% CR rate in a group of transformed NHL patients. A multicentric phase II study with a single dosimetric and therapeutic dose of Bexxar ® was conducted in 47 patients with relapsed or refractory low-grade (79%) or transformed low-grade (21%) B-cell NHL. Patients were heavily pretreated with median of four prior chemotherapy cycles and showed extensive disease. The study obtained 57% ORR of all the treated patients and 32% CR. The median TTP was 11.6 months and MDR was 9.9 months 38 . Davies et al. 13 performed a phase II study to assess the efficacy of Bexxar ® at first or second recurrence on 41 patients with indolent or transformed indolent B-cell NHL. During the follow-up of 3 years, they obtained ORR of 76%, CR of 49%, with 9.6 months of TTP and 15 months of MDR.
The Bexxar ® regimen was also performed in previously untreated NHL patients (Table 4 ). In a study on 76 previously untreated stage III or IV follicular NHL patients receiving Bexxar® as a sole treatment, after a median followup of 5.1 years, Kaminski et al. 39 observed a 95% ORR, 75% CR with a TTP of 73.2 months and a median PFS of 6.1 years. Among patients who achieved complete remission, 70% remained in remission for 4.3-7.7 years. Press et al. 40 conducted a phase 2 trial that included six cycles of CHOP chemotherapy followed by Bexxar ® in 90 patients with advanced stage follicular NHL. The results of this trial shows 90% ORR and 67% CR, while 57% of patients who achieved less than CR with CHOP improved their response after Bexxar ® therapy (49% patients converted from PR to CR/unconfirmed CR (Cru), while 4.9% patients changed from CRu into CR). With a median follow-up of 27.6 months, the 2-year PFS was estimated to be 81%, with 97% of the 2-year overall survival. Another Bexxar ® trial in patients with previously untreated non-Hodgkin lymphoma reported 100% ORR and 83% CR with follow-up of 52.8 months 41 . In different study, Bexxar ® regimen was administered after a short chemotherapeutic course of Fludarabine for 3 cycles in 35 previously untreated, stage III or IV follicular grade NHL CD20 lymphoma. The results of this study showed 100% of ORR to the complete regimen, and 86% of CR during the median follow-up of 58 months. The median duration of response was not reached. PFS was also not reached but was estimated to exceed 48 months 42 . A singlearm open-labeled multicenter phase II trial was performed on 32 patients who had initially responded to Bexxar ® and were retreated with Bexxar ® after relapse of the disease. Authors 43 reported 56% of ORR and 25% of CR, with 35 months of MDR in patients with CR. Retreatment with Bexxar ® was also studied in 16 relapsed NHL patients who initially responded to the first regimen and achieved ORR and CR in 56% and 31% of patients, respectively 38 .
Safety
RIT using either molecular regimens, Zevalin ® and Bexxar ® seems to be a safe. The most frequent toxicity reported was bone marrow suppression, transient and reversible. Hematologic toxicity includes neutropenia and thrombocytopenia, was delayed in onset with nadir between 7-9 weeks after the regimen and recovery after 2-3 weeks. More than a half of treated patients show platelet nadir below 50,000 per mm 3 , and approximately 20% will have a nadir below 25,000 per mm 3 and may require platelet transfusion. Absolute neutrophil counts below 500 per mm 3 may be detected in about 25-30% of treated patients with a month nadir duration. Hospitalization for febrile neutropenia or similar hematopoetic suppression develops in less than 10% 22 . Some authors 44 reported that Bexxar ® causes significantly less severe declines in platelet counts than Zevalin ® and thus may be better treatment option for patients with limited bone marrow reserve. Press et al. 40 conducted Bexxar ® regimen and obtained grade 3-4 neutropenia, thrombocytopenia and anemia in 15.8%, 13.4% and 2.4%, respectively. In contrast, the most recent study with the Zevalin ® regimen, reported 34% incidence of grade 3-4 neutropenia, 38% of thrombocytopenia and 8% of anemia, however, patients spontaneously recovered 33 . Compared to cytotoxicity caused by chemotherapy, nonhematologic adverse effects from either Zevalin ® or Bexxar ® are very mild. These toxicities are related mostly to minor allergic reactions to the protein components of the cold antibody, generally greater for patients treated with rituximab than those treated with tositumomab. In these situations, infusion should be adjusted to a slower rate. Asthenia or nausea was reported in about 20-40% after receiving either of the anti-CD20 compounds. Side effects such as hair loss, severe mucositis and persistent nausea or vomiting were not detected 44 . Potential long-term adverse effects might be hypothyroidism, development of human antimouse antibodies and secondary malignancies. Human antimouse antibody was reported in 10% of patients following Bexxar ® ; human antichimeric antibody was detected in about 1-2% following Zevalin ® 22 . However, this adverse effect is without serious clinical consequences 38 . Hypothyroidism develops in about 10-20% of patients treated with Bexxar ® despite the pretreatment of thyroid-blocking medications 22 . The most important late effect of RIT is secondary malignancy which includes myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Witzig et al. 45 reported 1-2% incidence of MDS/AML for lymphoma patients treated with Zevalin ® . Emmanoulides et al. 46 detected annual incidence of 0.34% for MDS and 0.7% for AML since initial treatment with Zevalin ® for the period 1993-2002. However, the review of the literature showed 4-8% rate of secondary malignancy in NHL patients treated with chemotherapy alone or combined with radiation therapy [47] [48] [49] . In a large study on 1,071 NHL patients treated with Bexxar ® , MDS and AML was reported with an annualized incidence of 1.4% per year (95% CI; 1-2% per year) 50 . In another study, there were no cases of MDS or AML 13 . These late toxic effects of bone marrow occur late in patients with B-cell NHL no matter how they are treated. Patients treated with either regimen, Bexxar ® or Zevalin ® , did not show increased incidence of MDS/AML 22 . In the extensive literature review Cheung et al. 51 reported that secondary MDS and AML had been reported of 0-8% in treated patients, and 0-3% in untreated patients.
Radiation exposure
RIT with either agents, Zevalin ® and Bexxar ® , is generally considered an outpatient therapy in the US. This treatment, in general, should not be performed in children and adolescents under 18 years of age, in pregnant and in lactating women.
The Zevalin ® regimen includes radionuclide 90 Y, which is pure beta emitter without gamma radiation. However, the bremsstrahlung emission radiation (which is emitted out of beta particle loosing energy process) is below the limit of exposure and is not hazardous for health personnel and family members. However, patients are provided by written instructions about contact with household members. They are suggested to avoid transmission of excretions such as saliva, blood, urine, seminal fluid and stool 52, 53 . According to the data published from another study, the Zevalin ® regimen includes minimal exposure to treated patients (0.00295 mSv/h at 1 m immediately after dosing). Exposure to patient's fam- ily members (first week 0.035 mSv) is in the range of European background radiation (0.04-0.15 mSv/week) 54 . According to the Nuclear Regulatory Commision and specific dose-calculations, virtually all patients can be released at the end of the therapeutic infusion. A study in Nebraska included family members of patients who had received 1-5 GBq of Bexxar ® to deliver 30-75 cGy. Measurement of monitoring devices of 26 family members from 22 patients showed radiation absorbed dose differ from 17 to 409 mrem (below 500 mrem limit applicable to general public members), based on patients receiving Bexxar ® (limit exposure to the total effective dose does not exceed 500 mR) 55 . Bexxar ® therapeutic regimen can be administered safely with minimal additional exposure to healthcare professionals. Harwood et al. 56 studied exposure on professional workers who were involved in 300 administrations of Bexxar ® treatment: radiopharmacists, nuclear medicine technologists, nurses and physicians at four different institutions during 2-4.5 years. They reported that additional average radiation monthly exposure per healthcare worker involved in Bexxar ® regimen was 5.8 mrem. Before release, patients are given detailed instructions on the duration and proximity to others to minimize exposure such as: avoiding sleeping with other individuals for a week or more, not traveling by air for several days, and avoiding children and pregnant women for a week or longer. These instructions are based upon patient specific variables including administered dose, measured emission from the patient at the body surface and at 1 m, and biologic turnover rate calculated from dosimetry measurements 51 .
Other radioimmunotherapy compounds
In Australia, due to the lack of availability of the RIT regimen, Zevalin ® and Bexxar ® , Leahy et al. 57 developed a new hybrid regimen consisting of rituximab as the cold antibody and rituximab labeled with 131 I in patients with indolent nonHodgin's lymphoma. In a recent study, they achieved ORR of 76% and CR of 53% with a median survival over 4 years. At 6-7 weeks, they reported side effects such as grade 4 thrombocytopenia and neutropenia in 4%, and 16%, respectively.
Linden et al. 58 developed an anti-CD22 monoclonal antibody, radiolabeled with 90 Y and evaluated as 90 YEpratuzumab in combination with cold Epratuzumab for treatment of indolent NHLs. An ORR in 62% and CR in 25% of patients was achieved; ORR of 75% in indolent NHLs and 50% in aggressive NHL. Subsequently, Leonard et al. 59 reported a 24% response in patients with follicular NHL with median duration of the objective response of 79.3 weeks and median time to progression for responders of 86.6 weeks. The treatment was well tolerated with manageable hematologic toxicity.
Recently, a multicenter, fractionated dose phase I/II study with 90 Y-epratuzumab was performed on 64 patients with relapsed or refractory NHL. The results indicated that for 61 patients, a median PFS was 9.5 months, while ORR and CR were 62% and 84%, respectively. In addition, 17 patients previously treated with autologous stenc cell transplantation, ORR of 71% and 55% CR were achieved. On the other hand, in patients with indolent follicular lymphoma, the ORR was 100% with CR of 92% and a PFS of 18.3 months 60 . Sharkey et al. 61 suggested that combining anti-CD 20 and anti-CD 22 antibodies might be more efficient for NHL patients in future clinical trials. They also suggested the possible role of 177 Lu or an alpha particle emitter in the setting of minimal or occult disease.
Conclusion
Two radiolabeled antibodies (with different radiolabels) were approved as therapeutic agents in low grade nonHodgkin's lymphoma. There was no direct comparison between the two agents and currently Bexxar ® is unavailable. In general, clinical responses (complete response, partial response) with radioimmunotherapy after relapse are better, and of greater duration, than alternative or repeat chemotherapies. Radioimmunotherapy regimen is safe and effective even after multiple relapses following chemotherapy and/or rituximab (Rituxin ® ) therapy. The complete response and overall response rate is even better when used in conjunction with first-line chemotherapy ("consolidation" treatment). The principle toxicity is hematologic, secondary to bone marrow irradiation from labeled antibody in blood and specific deposition on tumor cells in the bone marrow. Radioimmunotherapy should not be performed in patients younger than 18 years, pregnant or lactating women. Radiation exposure of family members and health care personnel is low. In the event of relapse, patients tolerate subsequent therapy as well or better than equivalent populations who have not received radioimmunotherapy.
During the last few years, new agents for radioimmunotherapy have been developed such as 131 I-rituximab therapy and 90 Y-epratuzumab, showing impressive results. Hopefully, future trials should investigate the combination of immunoglobulins and introduce new radionuclides including alpha emitters for radioimmunotherapy of patients with nonHodgkin lymphoma.
